TW202342096A - 靶向dll3的癌症治療 - Google Patents

靶向dll3的癌症治療 Download PDF

Info

Publication number
TW202342096A
TW202342096A TW112106776A TW112106776A TW202342096A TW 202342096 A TW202342096 A TW 202342096A TW 112106776 A TW112106776 A TW 112106776A TW 112106776 A TW112106776 A TW 112106776A TW 202342096 A TW202342096 A TW 202342096A
Authority
TW
Taiwan
Prior art keywords
dll3
agent
dose
administered
day
Prior art date
Application number
TW112106776A
Other languages
English (en)
Chinese (zh)
Inventor
紗卓尹 諾欣 哈雪米
牧可 密諾察
雅曼達 葛瑞克
曦 陳
蜜拉 琪絲樂
Original Assignee
美商安進公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商安進公司 filed Critical 美商安進公司
Publication of TW202342096A publication Critical patent/TW202342096A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW112106776A 2022-02-23 2023-02-23 靶向dll3的癌症治療 TW202342096A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263313119P 2022-02-23 2022-02-23
US63/313,119 2022-02-23
US202263429311P 2022-12-01 2022-12-01
US63/429,311 2022-12-01

Publications (1)

Publication Number Publication Date
TW202342096A true TW202342096A (zh) 2023-11-01

Family

ID=85724660

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112106776A TW202342096A (zh) 2022-02-23 2023-02-23 靶向dll3的癌症治療

Country Status (12)

Country Link
US (1) US20250154247A1 (cg-RX-API-DMAC7.html)
EP (1) EP4482586A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025508786A (cg-RX-API-DMAC7.html)
KR (1) KR20240153575A (cg-RX-API-DMAC7.html)
AU (1) AU2023224210A1 (cg-RX-API-DMAC7.html)
CA (1) CA3252459A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024002529A1 (cg-RX-API-DMAC7.html)
IL (1) IL314195A (cg-RX-API-DMAC7.html)
JO (1) JOP20240188A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024010330A (cg-RX-API-DMAC7.html)
TW (1) TW202342096A (cg-RX-API-DMAC7.html)
WO (1) WO2023164474A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025080688A1 (en) * 2023-10-12 2025-04-17 Amgen Inc. Compositions of bispecific antibody constructs to human dll3 and human cd3
TW202602488A (zh) * 2024-03-11 2026-01-16 美商安進公司 治療dll3陽性癌症受試者中腦轉移之方法
WO2026008059A1 (en) * 2024-07-04 2026-01-08 Nanjing Legend Biotech Co., Ltd. Anti-dll3 constructs and uses thereof
WO2026075950A1 (en) * 2024-10-01 2026-04-09 Amgen Inc. Dosing regimen for anti-dll3 agent
US20260216330A1 (en) * 2024-11-20 2026-07-30 Boehringer Ingelheim International Gmbh Use of t-cell engaging proteins in the treatment of cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2326389C (en) 1998-04-21 2007-01-23 Micromet Gesellschaft Fur Biomedizinische Forschung Mbh Novel cd19xcd3 specific polypeptides and uses thereof
US8076459B2 (en) 2003-10-16 2011-12-13 Micromet Ag Multispecfic deimmunized CD3-binders
WO2008119567A2 (en) 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific cd3-epsilon binding domain
EP3337517A4 (en) * 2015-08-20 2019-04-17 Abbvie Stemcentrx LLC ANTI-DLL3 ANTIBODY AGGREGATE CONJUGATES AND METHOD OF USE
JP7314146B2 (ja) 2017-12-28 2023-07-25 中外製薬株式会社 細胞傷害誘導治療剤
TWI848953B (zh) 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
CN119306844A (zh) 2018-09-25 2025-01-14 哈普恩治疗公司 Dll3结合蛋白及使用方法
EP3819312A1 (en) * 2019-11-10 2021-05-12 Amgen, Inc Dosing regimen for anti-dll3 agents
US11976133B2 (en) 2020-01-31 2024-05-07 Gensun Biopharma Inc. Bispecific T cell engagers
CA3173587A1 (en) 2020-03-31 2021-10-07 Chugai Seiyaku Kabushiki-Kaisha Dll3-targeting multispecific antigen-binding molecules and uses thereof
WO2022240688A1 (en) * 2021-05-10 2022-11-17 Amgen Inc. Dosing regimen for combination therapy targeting dll3 and pd-1

Also Published As

Publication number Publication date
JP2025508786A (ja) 2025-04-10
US20250154247A1 (en) 2025-05-15
EP4482586A1 (en) 2025-01-01
MX2024010330A (es) 2024-08-30
WO2023164474A1 (en) 2023-08-31
CA3252459A1 (en) 2023-08-31
CL2024002529A1 (es) 2025-01-24
JOP20240188A1 (ar) 2024-08-19
IL314195A (en) 2024-09-01
AU2023224210A1 (en) 2024-07-18
KR20240153575A (ko) 2024-10-23

Similar Documents

Publication Publication Date Title
US11866509B2 (en) Humanized antibodies against CEACAM1
US20250154247A1 (en) Cancer treatment targeting dll3
US20240317856A1 (en) Dosing regimen for combination therapy targeting dll3 and pd-1
US11591395B2 (en) Methods of treating prostate cancer with an anti-PSMA/CD3 antibody
KR20220097470A (ko) 항-dll3 작용제의 투여 요법
US20230074793A1 (en) Treatment with a bispecific antibody that binds ctla4 and pd1
CA3136892A1 (en) Methods of treating renal cancer with an anti- psma/cd3 antibody
KR20240028452A (ko) 암을 치료하기 위한 방법 및 조성물
JP2024511977A (ja) 抗ilt3抗体によるがんの治療方法
CN118785922A (zh) 靶向dll3的癌症治疗
US11427647B2 (en) Polynucleotides encoding humanized antibodies against CEACAM1
US20240092934A1 (en) Assessment of ceacam1 expression on tumor infiltrating lymphocytes
TW202436335A (zh) 治療表現dll3的癌症之方法
WO2024102645A1 (en) Combination treatment with a bispecific antibody that binds ctla4 and pd1 for prostate cancer
HK40112915A (en) Anti-galectin-9 antibodies and therapeutic uses thereof
TW202612729A (zh) 涉及抗hla-g抗體及抗egfr抗體以及抗pd-1抗體之組合療法
HK40110052A (en) Methods and compositions for treating cancer
CN118251234A (zh) 抗半乳糖凝集素-9抗体及其治疗用途
WO2020135415A1 (zh) 抗pd-l1单克隆抗体治疗癌症的用途